Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
SLU-PP-332 is a synthetic ERR agonist that mimics aerobic exercise at the gene level. Mouse data show 12% weight loss and 70% longer running times in 28 days. No human trials exist. Community protocols use 10 to 50 mg/day subcutaneous injection.
10mcg · Daily
Summary: Add 2mL BAC water to your 10mg vial. Draw to 0.2 units on a U-100 syringe for a 10mcg dose. This vial will last 1000 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 25mg | Daily |
| Aggressive | 50mg | Daily |
This is a small molecule, not a peptide. Reconstitution math depends on your vial and solvent choice. SLU-PP-332 dissolves in DMSO or can be reconstituted with bacteriostatic water for subcutaneous injection. For a 25 mg vial reconstituted with 1 mL bacteriostatic water: concentration is 25 mg/mL. A 10 mg dose is 40 IU on a U100 insulin syringe (0.4 mL). A 25 mg dose uses the full syringe (100 IU / 1.0 mL); consider splitting across two injection sites at that volume. For a 10 mg vial reconstituted with 0.5 mL: concentration is 20 mg/mL. A 10 mg dose is 50 IU (0.5 mL). The mcg versus mg confusion tripped up a lot of early adopters. If you're dosing in the 250 to 1,500 mcg range, you're almost certainly too low. Community consensus settled on 10 to 50 mg/day subcutaneous as the effective range. Oral bioavailability is widely described as "nearly useless" for hitting meaningful plasma levels. Get an ECG before your first cycle. That's the single most important safety step given the cardiac data.
Dosing based on Preclinical data only: no human dosing data established — 10 published references.View all sources →
Cross-check your SLU-PP-332 reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
SLU-PP-332 is a synthetic ERR agonist that mimics aerobic exercise at the gene level. Mouse data show 12% weight loss and 70% longer running times in 28 days. No human trials exist. Community protocols use 10 to 50 mg/day subcutaneous injection.